Sleep Disorder Clinical Trial
Official title:
NIA_Improving Sleep and Circadian Functioning, Daytime Functioning, and Well-being for Midlife and Older Adults by Improving Patient Memory for a Transdiagnostic Sleep and Circadian Treatment
Mental illness is often chronic, severe, and difficult to treat. Though there has been significant progress towards establishing effective and efficient interventions for psychological health problems, many individuals do not gain lasting benefits from these treatments. The Memory Support Intervention (MSI) was developed utilizing existing findings from the cognitive science literature to improve treatment outcomes. In this study, the investigators aim to conduct an open trial that includes individuals 50 years and older to assess if a novel version of the Memory Support Intervention improves sleep and circadian functioning, reduces functional impairment, and improves patient memory for treatment.
Status | Recruiting |
Enrollment | 178 |
Est. completion date | July 28, 2028 |
Est. primary completion date | February 28, 2028 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 50 Years and older |
Eligibility | Inclusion criteria: 1. Aged 50 years and older; 2. English language fluency; 3. Experiencing a mobility impairment; 4. Low income; 5. Exhibit a sleep or circadian disturbance as determined by endorsing 4 "quite a bit" or 5 "very much" (or the equivalent for reverse scored items) on one or more PROMIS-SD questions. 6. 25-30 on the Montreal Cognitive Assessment, as a negative screen for cognitive impairment. 7. Able/willing to give informed consent. Exclusion criteria: 1. Severe untreated sleep disordered breathing (AHI>30) or moderate untreated sleep disordered breathing with severe daytime sleepiness (AHI of 15-30 and Epworth Sleepiness Scale >10); 2. Medical conditions that prevent a participant from comprehending and following the basic tenants of treatment (e.g., dementia) or that interfere with sleep in a manner that can't be addressed by a cognitive behavioral treatment (e.g., the Structured Clinical Interview for Sleep Disorders will be used to screen for narcolepsy, REM sleep behavior disorder) or that may preclude full participation (e.g., receipt of end of life care); 3. Homelessness; 4. Night shift work >2 nights per week in the past 3 months; 5. Substance abuse/dependence only if it makes participation in the study unfeasible; 6. Suicide risk sufficient to preclude treatment on an outpatient basis. |
Country | Name | City | State |
---|---|---|---|
United States | University of California, Berkeley | Berkeley | California |
Lead Sponsor | Collaborator |
---|---|
University of California, Berkeley |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | WatchPAT One | For participants who screen positive for obstructive sleep apnea, WatchPAT One will be offered to determine eligibility | Baseline only | |
Other | Adverse events checklist | To assess any adverse events experienced as a result of participating in the study | Only at post-treatment which is 8-10 weeks after the beginning of treatment | |
Other | Montreal Cognitive Assessment (MoCA) | A measure of cognitive functioning/cognitive impairments to determine eligibility | Baseline only | |
Other | Adapted Credibility Expectancy Questionnaire | Measures the credibility and expectation of improvement from the treatment. | At treatment Week 2 and at post-treatment which is 8-10 weeks after the beginning of treatment | |
Other | Structured Clinical Interview for Sleep Disorders | Measures sleep and circadian diagnoses according to DSM-5 | Baseline only | |
Other | Adapted Brief Disability Questionnaire | A measure of functional impairment | Baseline only | |
Primary | Patient-Reported Outcomes Measurement Information System - Sleep Disturbance | Assesses perceived functional impairments related to sleep problems using a self-report questionnaire. The minimum value is 8. The maximum value is 40. Higher scores mean more sleep disturbance (worse outcome). | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment to 6-month follow-up to 12-month follow-up | |
Primary | Sheehan Disability Scale | Assesses functional impairment on a scale from 0 to 30, where higher scores mean higher impairment | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment to 6-month follow-up to 12-month follow-up | |
Primary | Satisfaction with Life Scale | 5-item instrument designed to measure global cognitive judgements of satisfaction with one's life. Scores can range from 5-35 with higher scores indicating higher levels of satisfaction with life. | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment to 6-month follow-up to 12-month follow-up | |
Secondary | Patient-Reported Outcomes Measurement Information System - Sleep Related Impairment | Assesses perceived functional impairments related to sleep problems in a self-report questionnaire. The minimum value is 16. The maximum value is 80. Higher scores mean more sleep related problems (worse outcome). | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment to 6-month follow-up to 12-month follow-up | |
Secondary | Positive and Negative Affect Scale | Positive affect scores can range from 10-15, with higher scores representing higher levels of positive affect. Negative affect scores can range from 10-50, with lower scores representing lower levels of negative affect | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment to 6-month follow-up to 12-month follow-up | |
Secondary | WHODAS 2.0 | A measure of functional impairment | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment to 6-month follow-up to 12-month follow-up | |
Secondary | Cognitive Failures Questionnaire | Used to assess the frequency with which people experienced cognitive failures. Scores range from 0-100, with higher scores indicating higher levels of cognitive failures. | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment to 6-month follow-up to 12-month follow-up | |
Secondary | Epworth Sleepiness Scale | Used to assess daytime sleepiness. Scores can range from 0-24 with higher scores indicating higher levels of daytime sleepiness. | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment to 6-month follow-up to 12-month follow-up | |
Secondary | Memory for Treatment: Cumulative recall | Recall on the Patient Treatment Recall Task | Week 4 of treatment as well as Post Treatment, defined as two weeks after the final therapy session (i.e. 8-10 weeks after the initial intake interview) to 6-month follow-up to 12-month follow-up] | |
Secondary | Thoughts and Applications Task | Measures how treatment points have generalized to the participant's thinking and functioning during every day life | Week 4 of treatment as well as Post Treatment, defined as two weeks after the final therapy session (i.e. 8-10 weeks after the initial intake interview) to 6-month follow-up to 12-month follow-up] | |
Secondary | Adapted Utilization Scale | 19-item; 0-4 scale. Scores can range from 0 to 76 (Higher score means more utilization). | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment to 6-month follow-up to 12-month follow-up | |
Secondary | Composite Sleep Health Score | Composite Sleep Health Score which is defined as the sum of scores on 6 sleep health dimensions: Regularity (Midpoint fluctuation), Satisfaction (Sleep quality question on PROMIS-SD), Alertness (Daytime sleepiness question on PROMIS-SRI), Timing (Mean midpoint), Efficiency (Sleep efficiency) and Duration (Total Sleep Time). | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment to 6-month follow-up to 12-month follow-up | |
Secondary | Mean sleep efficiency (Daily Sleep Diary) | Daily Sleep Diary mean for sleep efficiency (total sleep time/time in bed X 100) | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment to 6-month follow-up to 12-month follow-up | |
Secondary | Mean total wake time (Daily Sleep Diary) | Daily Sleep Diary mean for total wake time defined as sleep onset latency + wake after sleep onset + Early morning awakening | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment to 6-month follow-up to 12-month follow-up | |
Secondary | Mean for total sleep time (Daily Sleep Diary) | Daily Sleep Diary mean for total sleep time | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment to 6-month follow-up to 12-month follow-up | |
Secondary | Mean for total wake time (Actigraphy) | Actigraphy mean for total wake time defined as sleep onset latency + wake after sleep onset + early morning awakening | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment | |
Secondary | Mean for total sleep time (Actigraphy) | Actigraphy mean for total sleep time | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment | |
Secondary | Mean for daytime activity (Actigraphy) | Actigraphy mean for daytime activity | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment | |
Secondary | Provider level: Acceptability of Intervention Measure | Assess provider perceptions of the acceptability of the treatment intervention using a self-report questionnaire | Through therapy completion, an average of 8 weeks following baseline | |
Secondary | Provider level: Appropriateness Intervention Measure | Assesses provider perceptions of the appropriateness of the treatment intervention using a self-report questionnaire | Through therapy completion, an average of 8 weeks following baseline | |
Secondary | Provider level: Feasibility of Intervention Measure | Assesses provider perceptions of the feasibility of the intervention using a self-report questionnaire | Through therapy completion, an average of 8 weeks following baseline | |
Secondary | Provider level: Provider-rated TranS-C Checklist | A measure of the TranS-C elements that are delivered. This is completed by the therapist at the end of every treatment session | Every treatment session which is 8 sessions, spaced one week apart for approximately 8-10 weeks | |
Secondary | Provider level: Memory Support Treatment Provider Checklist | A measure of memory support delivered. This is completed by the therapist at the end of every treatment session | Every treatment session which is 8 sessions, spaced one week apart for approximately 8-10 weeks | |
Secondary | Provider level: Patient adherence via the TARS | A measure of patient treatment adherence completed by the therapist at the end of every treatment session | Every treatment session which is 8 sessions, spaced one week apart for approximately 8-10 weeks | |
Secondary | Provider level: Memory Support Rating Scale, total amount | Assesses the total amount of memory support used by a provider via coding of session tapes | Randomly selected therapy tapes | |
Secondary | Provider level: Memory Support Rating Scale, number of types | Assesses the number of types of memory support used by a provider via coding of session tapes | Randomly selected therapy tapes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Recruiting |
NCT04786314 -
The Effect of Hot and Cold Water Application on Pregnant Women With Restless Leg Syndrome
|
N/A | |
Recruiting |
NCT05775731 -
Markers of Inflammation and of the Pro-thrombotic State in Hospital Shift and Day Workers
|
||
Recruiting |
NCT03326765 -
Characterizing Sleep Disorders in Children and Adults With Tuberous Sclerosis Complex (TSC)
|
N/A | |
Completed |
NCT03673397 -
The Acute Effect of Aerobic Exercise on Sleep in Patients With Depression
|
N/A | |
Completed |
NCT03903263 -
Sleep Disturbances in Dermatology Patients
|
||
Not yet recruiting |
NCT05950932 -
Effects of Melissa Extract on Sleep Characteristics
|
Phase 4 | |
Not yet recruiting |
NCT06012513 -
Sleep Disorders and Quality of Life in Patients With Multiple Sclerosis
|
||
Completed |
NCT01463839 -
Sleep Disorder and Oral Habits in Children
|
N/A | |
Completed |
NCT00940589 -
Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor
|
Phase 2 | |
Recruiting |
NCT06093633 -
A Prospective Study to Evaluate the WP in Comparison to PSG in Patients Suspected of Sleep Disorders
|
||
Completed |
NCT06108115 -
Smartphone-Based Intervention for Sleep Disturbance in Individuals Recovering From Alcohol Use Disorder
|
N/A | |
Completed |
NCT05511818 -
Radicle Rest: A Study of Cannabinoids on Sleep and Health Outcomes
|
N/A | |
Active, not recruiting |
NCT04291014 -
Light Therapy for PD - Dose Selection
|
N/A | |
Completed |
NCT04560595 -
Remote Guided Caffeine Reduction
|
N/A | |
Completed |
NCT06008470 -
Investigation of Respiratory Muscle Strength, Exercise Capacity, Physical Activity and Sleep Quality Level in Individuals With Covid-19 Infection
|
||
Recruiting |
NCT06129942 -
Light Therapy in Parkinson's Disease
|
N/A | |
Recruiting |
NCT04318067 -
Melatonin in ADHD and Sleep Problems
|
Phase 4 | |
Completed |
NCT03857802 -
Efficiency of a Nursing Intervention in Sleep Hygiene
|
N/A | |
Completed |
NCT03532269 -
Validation of the Sleep Assessment Algorithm in the Medical Application Nightly
|
N/A |